[stock_market_widget type=”card” template=”basic2″ assets=”CVRX” realtime=”true” api=”yahoo-finance”]
Every so often, one investor decides that a private disagreement ought to become a public argument. That is what happened this week to CVRx, Inc. (NASDAQ: CVRX), a Minneapolis medical device maker most people outside the heart failure world have never heard of. Yesterday, a shareholder named Jorey Chernett, who runs an investment firm called Pointillist Family Office and owns more than 5.5% of the company, sent an open letter to the board asking it to sell the business to a larger rival. Today, CVRx answered in public.
To understand why this matters, it helps to know what the company actually sells. Its main product is Barostim, an implantable device that sends small electrical pulses to sensors in the wall of an artery in the neck. The goal is to nudge the nervous system back into balance and ease the symptoms of heart failure. It is the only device of its kind that the U.S. Food and Drug Administration has approved for that use, and it carries the agency’s breakthrough designation. This is a company built around one distinctive product and a narrow but real medical niche.
Chernett’s argument is that the scarcity is the point. In his letter, he says Barostim would be far more valuable inside a big medical device company that already has the sales force to sell it widely. A deal, he claims, could start adding to a buyer’s earnings within a year and would hand shareholders more money than CVRx could realistically produce alone. He asked the board to hire an independent advisor, to run a formal review with a sale as the priority, to cut executive pay and overhead in the meantime, and to publish a clear timeline. His warning was blunt: move now, while the cash and momentum last, rather than negotiate later from weakness.
What makes the response interesting is how much the two sides agree on. The board did not brush him off. It said it welcomes his input and has been talking with him. It agreed that Barostim is a genuinely differentiated therapy backed by strong clinical evidence, and, notably, it agreed that the current share price does not reflect what the business is worth. Where the company parts ways is on the remedy. Management says it is confident in its own plan to grow Barostim sales while controlling spending, and it framed a sale as just one of many options it weighs regularly.
For anyone watching the stock, the timing is hard to ignore. CVRx shares have climbed roughly 18% over the past five trading days, a move that suggests that maybe the investors are taking the sale talk seriously. The company has had a rough stretch this year, with several analysts trimming their price targets after a cut to its revenue outlook, so a jolt of takeover speculation has landed on already nervous ground.
One more piece of context is worth adding, because it is not in the CVRx statement. Chernett has run this same play before. Earlier in 2026 he pressed Neuronetics, Inc. (NASDAQ: STIM), a maker of a depression treatment device, to explore a sale, and he pushed SEACOR Marine Holdings Inc. (NYSE: SMHI), an offshore vessel operator, to sell its fleet or itself. The pattern is consistent: he finds a company he believes the market is underpricing, then campaigns loudly for a sale.
So where does this leave CVRx? The board has committed to nothing beyond continued conversation and its existing plan, which means the real test is what it does over the coming months rather than what it said this week. Both sides claim to want the same thing, a higher value for the people who own the shares. They simply disagree about whether the faster route runs through a buyer or through the company’s own strategy, and that disagreement is now playing out in full view.
